More on BD fiscal Q2 results

|By:, SA News Editor

Revenues: $2.072B (+3.6%), Medical: $1.116B (+5.1%), Diagnostics: $653M (+0.9%), Biosciences: $302M (+8.2%).

EPS: $1.45 (+4.3%).

Updated F14 guidance:

Revenue growth: 4% - 4.5%.

EPS: $6.14 - $6.17, down from $6.19 - $6.22.

(BDX)